Activation in Fronto-Parietal Networks Normalizes After Cognitive Therapy
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Feb. 1, 2024 -- For unmedicated youths with anxiety disorder, activation in fronto-parietal networks may normalize after cognitive behavioral therapy (CBT), according to a study published online Jan. 24 in The American Journal of Psychiatry.
Simone P. Haller, D.Phil., from the National Institute of Mental Health in Bethesda, Maryland, and colleagues examined the brain mechanisms associated with symptom change following CBT among unmedicated youths diagnosed with an anxiety disorder. Participants underwent 12 weeks of CBT as part of two randomized clinical trials. Before and after treatment, a threat-processing task was completed by 69 youths with anxiety disorder during magnetic resonance imaging. During the same time span, 62 age-matched healthy comparison youths also completed two scans. The stability of anxiety-related neural differences was tested in the absence of treatment in an additional sample of 87 youths at temperamental risk for anxiety.
The researchers found that across all task conditions, patients with an anxiety disorder exhibited altered activation in fronto-parietal attention networks and limbic regions relative to healthy comparison children before treatment. During the course of treatment, fronto-parietal hyperactivation normalized, while limbic responses remained elevated following treatment. In the at-risk sample, regions showing stable associations with anxiety over time and regions showing treatment-related changes had overlapping clusters.
"The data from this study reveal neural mechanisms that change following the acute effects of CBT for pediatric anxiety, as well as potential subcortical and cortical targets that remain dysfunctional after 12 weeks of CBT," the authors write.
One author reported ties to various medical organizations.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-02-02 04:15
Read more

- Staying Active Might Slow Parkinson's Progression
- Johnson & Johnson Seeks First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
- Sebela Pharmaceuticals Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 24-Week Maintenance Phase Results
- Insomnia Plays a Role in Quality of Life for Patients With ADHD
- U.S. FDA Granted Fast Track Designation to Dizal’s Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Lilly's Oral GLP-1, Orforglipron, Delivers Weight Loss of Up To an Average of 27.3 lbs in First of Two Pivotal Phase 3 Trials in Adults with Obesity
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions